Connect with us

Technology

Amid Record Growth and Adoption of Judi Clinical Trial Collaboration Platform, AG Mednet Announces New Key Leadership Appointments

Published

on

BOSTON, Sept. 10, 2024 /PRNewswire/ — AG Mednet, the pioneering force in clinical trial process management, continues to experience rapid growth and momentum, driven by the widespread adoption of its Judi platform on over 2,000 clinical trials across 640 drug and device sponsors and 90 Contract Research Organizations (CROs), Core Labs, and Academic Research Organizations (AROs) globally. In response to this surge in adoption and AG Mednet’s unwavering commitment to delighting its partners and clients, the company is pleased to announce the addition of two key hires: Catherine Tyner as Head of Clinical Strategy, and Jamie Russo as Head of Product. These appointments reinforce AG Mednet’s dedication to maintaining the highest standards of innovation, service, quality, and client-centricity in the face of unprecedented demand for the Judi platform.

Due to widespread adoption of Judi, AG Mednet has made the strategic decision to expand its leadership team.

Due to rapidly increasing demand and widespread adoption of Judi, AG Mednet has made the strategic decision to expand its leadership team to meet the needs of the growing client base. The Judi platform continues to be the go-to solution for organizations looking to simplify essential aspects of clinical trial conduct, enhance collaboration, and drive efficiencies across their development portfolios in mission-critical areas such as clinical event and endpoint adjudication, centralized eligibility determination, medical imaging, remote monitoring, and more.

Catherine Tyner joins AG Mednet as Head of Clinical Strategy, where she brings 27 years of clinical research experience with a focus on Oversight Group Management for Clinical Endpoint Committees, Data Monitoring Committees, and other pharmacovigilance operations. Throughout her career, Ms. Tyner has led and developed oversight departments at Quintiles (now IQVIA), Novella Clinical, and Covance (now Fortrea), providing strategic management for over 500 clinical trials, including complex megatrials across diverse therapeutic areas. A recognized thought leader in endpoint adjudication best practices, Ms. Tyner has authored the industry’s seminal guidance on adjudication operations and best practice. In her new role at AG Mednet, Ms. Tyner will work to expand and tailor the value jointly created with new and existing CROs Trial Sponsors, Core Labs, and Academic Research Organizations, working closely to optimize the future of clinical process efficiency.

“I’m thrilled to be joining AG Mednet as Head of Clinical Strategy at such a pivotal time,” says Tyner. “Having worked with AG Mednet and experienced the flexibility of their team, and the Judi platform from a CRO’s perspective, I can say without hesitation that they are leading the way in innovation for clinical process management. Their commitment to excellence and their impact on centralized adjudication, data monitoring committees, and eligibility best practices are unmatched. I’m excited to help drive even more progress in this space and contribute to the continued growth and adoption of the Judi platform,” Tyner added.

In her new role as Head of Product, Jamie Russo is responsible for driving product strategy and innovation across the entire portfolio of Judi solutions, including the implementation of AI-enabled solutions across the Judi ecosystem. With over a decade of experience in the healthcare and technology sectors, Ms. Russo previously held pivotal roles at leading organizations, including PathAI, where she served as Associate Director of Platform Product Management, and Massachusetts General Hospital, where she coordinated clinical research trials in both oncology and cardiovascular research. Ms. Russo’s expertise spans across product management and clinical operations, making her a key leader in advancing the intersection of technology and clinical research through the Judi platform. Ms. Russo holds a Bachelor of Arts in Neuroscience from Middlebury College.

Russo added:

“In my previous roles, I’ve worked to ensure that healthcare technology meets the evolving needs of clinical research, and I see AG Mednet as the clear leader in this space. The Judi platform’s success in helping sponsors and CROs manage clinical trials efficiently is a testament to the company’s vision and execution. I’m eager to help drive the next phase of growth and innovation as part of the AG Mednet team.”

Abraham Gutman, CEO of AG Mednet, commented:

“We are thrilled to welcome Jamie Russo and Catherine Tyner to the AG Mednet leadership team. As the Judi platform continues to see unprecedented demand and widespread adoption across the clinical development landscape, it’s more important than ever to bring in leaders who are experts and understand the nuances of both the technological and clinical applications of study conduct and oversight. Jamie and Catherine embody the excellence we are committed to, and their combined experience will help drive further innovation, ensuring that AG Mednet continues to lead the way in clinical trial process management.”

Unprecedented industry adoption & global usage:

New Partnerships: More than 100 unique trial sponsors have partnered with AG Mednet to adopt the Judi ecosystem over the last year, underscoring its status as the go-to solution for simplifying and optimizing mission-critical clinical processes.Diverse Industry Representation: Judi supports trials across 20 different therapeutic areas, including 900+ oncology, rare disease, and cardiometabolic trials, reflecting its versatility and ability to accommodate any study process parameters.Global Reach: With usage spanning 170 countries, Judi continues to enable cross-functional teams around the world to collaborate seamlessly, fostering global innovation in clinical development.

Looking ahead to 2025, AG Mednet remains focused on supporting the growing demand for Judi with quality and precision, advancing clinical research through AI-enabled solutions, and fostering meaningful collaborations to expedite novel therapies for patients worldwide.

About AG Mednet
AG Mednet revolutionizes the clinical trial process through Judi, its award-winning collaboration platform. Judi streamlines workflows, facilitates communication, and accelerates the development of life-saving therapies. Trusted by 640 global biopharmaceutical and medical device sponsors in 20 therapeutic areas across 2,000 clinical trials, and 5 of the top 6 global CROs, Judi delivers transparency and predictability for managing mission critical processes in clinical development, including endpoint adjudication, centralized patient eligibility, data safety monitoring, medical imaging, and more. For additional information, visit www.judi.io.

For media inquiries, contact:
Matt Cocking
mcocking@agmednet.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/amid-record-growth-and-adoption-of-judi-clinical-trial-collaboration-platform-ag-mednet-announces-new-key-leadership-appointments-302243793.html

SOURCE AG Mednet, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BitradeX BXC First Two Subscription Rounds Sell Out, Total Subscriptions Exceed 14M USDT

Published

on

By

LONDON, May 9, 2026 /PRNewswire/ — BitradeX Capital’s ecosystem equity token, BXC, has completed its first and second subscription rounds, selling a total of 50 million BXC with subscriptions exceeding 14 million USDT. The first round sold out in 90 seconds, while the second closed within 48 hours.

While the fundraising size is not unusually large by crypto standards, the structure of the sale has attracted market attention. The first two rounds were not open to the public, but limited to high-tier BitradeX users. The first round was available only to V5 users and above, while the second round expanded access to V3 users and above.

According to BitradeX’s tier system, V3+ users typically have higher recurring investment activity through AiBot, longer platform usage history, and stronger ecosystem participation. This means the early BXC allocation was absorbed mainly by the platform’s internal high-value user base, rather than short-term speculative participants.

This approach differs from many token fundraising campaigns that prioritize broad public participation and market hype. BitradeX instead adopted a more selective, staged model, gradually lowering the participation threshold while keeping the sale within its active ecosystem community.

BXC is positioned as more than a standard platform token. Its value framework is linked to BitradeX Capital’s broader ecosystem, including its exchange business, AiBot quantitative strategies, BTX Card payments, and Labs incubation platform. Public information indicates that BXC holders may receive staking rewards, benefit from ecosystem buybacks and burns, and gain priority access to Launchpad projects and governance participation.

The third subscription round is launched on April 30 at $0.35 USDT per BXC, with a total supply of 100 million BXC. It is now open to users participating in AiBot recurring investment. The fourth round price is expected to rise to $0.45 USDT.

The long-term value of BXC will ultimately depend on the growth of BitradeX’s underlying businesses, including exchange profitability, AiBot user expansion, and BTX Card adoption. However, the rapid sellout of the first two rounds suggests that BitradeX’s core user base has already shown strong confidence in the ecosystem’s future.

View original content:https://www.prnewswire.com/news-releases/bitradex-bxc-first-two-subscription-rounds-sell-out-total-subscriptions-exceed-14m-usdt-302767467.html

SOURCE BitradeX Capital

Continue Reading

Technology

South and East Asia identified as hotspots of global warming related impacts on male fertility

Published

on

By

BEIJING, May 9, 2026 /PRNewswire/ — A major new study has shown that South and East Asia dominate patterns of global warming related decline in male fertility with the strongest and most consistent evidence coming from India, Pakistan and the southern parts of China.

The effects of increased environmental temperatures on male reproductive health include declining sperm concentration and motility and increased sperm DNA fragmentation, or genetic damage that can hinder fertilisation and embryo development.

Male related factors account for around 50 per cent of infertility cases around the world and the impact of rising ambient heat on semen parameters raises serious implications across wide areas of Asia where total fertility rates are in serious decline.

Outcomes of the study undertaken by the Taiwan IVF Group and Ton Yen General Hospital, Taiwan (China) in collaboration with Stanford University (USA) are being presented at the 2026 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Beijing.

Research principal and Adjunct Clinical Assistant Professor at Stanford University, Dr Jack Yu Jen Huang, MD, PhD, FACOG said: “Given the temperature sensitivity of spermatogenesis, even modest increases in ambient temperature could have cumulative, population-level effects over time.

“As global warming accelerates, male reproductive health may represent an emerging climate sensitive public health concern.”

The testes function optimally at temperatures lower than the internal body heat level, and previous studies have shown elevated scrotal or ambient temperatures can impair sperm production.

The latest research explored global patterns to reveal comparative data across regions. It is based on a systematic review of international studies on temperature exposure and semen parameter trends between 2000 and 2024. Artificial intelligence algorithms and machine learning tools were applied to extract key variables including geographic regions and semen outcomes.

Dr Huang said studies examining occupational heat exposure alone were excluded from the analysis as they reflected localised, job-specific conditions rather than broader climatic trends.

“Our findings therefore represent population level climate associated temperature effects including consistent seasonal variations showing poor semen quality parameters in warmer periods.”

The global patterns on temperature associated lower sperm concentration and motility show South and East Asia as major hot spots of concern followed by the Middle East, Europe and North America.

“South and East Asia are likely more affected due to a combination of factors including higher baseline ambient temperatures and rapid urbanisation that contribute to greater cumulative heat stress on spermatogenesis,” Dr Huang explained.

“With ongoing global warming, chronic heat exposure may increasingly impact male reproductive health.”

Dr Huang said potential approaches to address the issue include:

increasing public awareness of heat exposure and reproductive health;encouraging protective behaviours;expanding research integrating climate and reproductive health data; andexploring clinical and lifestyle interventions to mitigate heat-related effects.

The research team was assisted by research intern Jeffrey Zi Kang Huang from Taipei American School, particularly in the application of artificial intelligence in biomedical research including AI-assisted data analysis and pattern recognition across global datasets.

“Further longitudinal and mechanistic studies will be important to better define causality and guide interventions,” he added.

The ASPIRE Congress is being held at the China National Convention Centre in Beijing. More than 3,000 scientists, clinicians, nurses and counsellors in assisted reproduction from around the world are attending the Congress.

For further information, go to https://www.aspire2026.com

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/south-and-east-asia-identified-as-hotspots-of-global-warming-related-impacts-on-male-fertility-302767469.html

SOURCE ASPIRE

Continue Reading

Technology

eclicktech Attends Amazon Ads unBoxed 2026, Highlighting Four Key Trends Shaping AI-Driven Global Marketing

Published

on

By

SHENZHEN, China, May 9, 2026 /PRNewswire/ — Amazon Ads recently hosted its annual flagship event, Amazon Ads unBoxed 2026, in Shenzhen, bringing together advertisers, agencies, and technology partners to explore the next phase of AI-powered marketing innovation. This year’s event focused on how AI is reshaping the advertising ecosystem through advancements in audience targeting, creative production, campaign management, and measurement capabilities.

Yeahmobi, the global marketing brand under eclicktech and an Amazon DSP validated partner, attended the event alongside industry leaders and ecosystem partners to discuss emerging opportunities for international brand growth in an increasingly AI-driven media environment.

During the conference, Amazon Ads introduced a series of product and solution updates across four major areas:

Advanced audience targeting powered by Amazon’s first-party data infrastructure to help brands reach high-intent consumers more effectively;AI-assisted creative production designed to improve content efficiency and support personalized advertising at scale;Intelligent campaign management tools aimed at simplifying cross-channel advertising workflows;Enhanced measurement and attribution capabilities to provide advertisers with clearer visibility into campaign performance and return on investment.

According to Yeahmobi, Amazon DSP is evolving beyond a standalone programmatic buying platform into a broader marketing infrastructure supporting the full customer journey, from brand awareness to conversion.

Since becoming an Amazon Ads partner, Yeahmobi has developed integrated advertising solutions spanning awareness, audience engagement, and conversion optimization. The company stated that it has supported brands across sectors including cross-border e-commerce, consumer electronics, AI applications, and financial services in scaling their global advertising efforts through Amazon DSP.

At the event, Yeahmobi also showcased its proprietary advertising management platform, Yeahgrowth, which integrates campaign management, data analytics, and performance optimization capabilities to support centralized multi-platform operations and improved campaign visibility.

“AI is fundamentally reshaping how brands approach global growth,” said William Liu, General Manager of Yeahmobi. “We see Amazon Ads as a strategically important part of the global marketing ecosystem. Our focus is not only on media execution, but also on building scalable growth infrastructure through deeper API integration, AI-driven optimization, and data collaboration.”

Yeahmobi stated that it will continue expanding its collaboration with Amazon Ads to support brands navigating increasingly complex global media environments.

About Yeahmobi
Yeahmobi is a global marketing brand focused on helping businesses achieve international growth through digital advertising, data-driven operations, and AI-powered marketing solutions.

Forward-Looking Statements
This press release contains forward-looking statements. Actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update any forward-looking statements.

 

View original content:https://www.prnewswire.com/news-releases/eclicktech-attends-amazon-ads-unboxed-2026-highlighting-four-key-trends-shaping-ai-driven-global-marketing-302767470.html

SOURCE Yeahmobi

Continue Reading

Trending